Enhancing risk-based Barrett’s esophagus screening through streamlined referral pathways

Gastrointestinal Endoscopy 2026 Open access

Read full text
Authors: Junseo B. Lee, Valeria Martinez Lebron, Julia L. Boland, Anushka Deogaonkar, Marie L. Borum, Samuel A. Schueler
DOI: 10.1016/j.gie.2025.11.014
Cited by: 0
References: 2

Abstract

We read with great interest the commentary by Dr Trindade, “A Bit Too Heated: Not All Dysplastic Barrett’s Esophagus Should Be Treated.”1 The call for a more selective approach to endoscopic eradication therapy is timely and clinically important. As Dr Trindade notes, not all dysplastic Barrett’s esophagus (BE) follows the same biological course, and treatment of all cases may expose patients to unnecessary risk while straining health care resources.

Fields of Study & Subjects

Esophageal Cancer Research and Treatment Esophageal and GI Pathology Gastroesophageal reflux and treatments

Publication details

Journal / source
Gastrointestinal Endoscopy
Volume
103
Issue
5
Pages
1095–1095
Publication date
3 February 2026
Language
EN